drugset / Trial / NCT04765644

Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment

NCT04765644

Phase 4 Completed 44 enrolled Imperial College London
RandomizedParallel-groupQuadruple-blindBasic science

Summary

A single centre, placebo controlled, blinded (participant, investigator, outcome assessor) trial to evaluate the effects of COX-2 inhibition with celecoxib on endothelial function in healthy male volunteers.

Timeline

Start
2021-06-10
Primary completion
2022-01-24
Completion
2022-01-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg

Indications

No indication recorded.